Indrayani Biotech Limited has secured a two-month extension from the Registrar of Companies (ROC), Chennai, to hold its 34th Annual General Meeting (AGM) for FY26. The new deadline is November 30, 2026.

The company applied for the extension under Section 96(1) of the Companies Act, 2013, citing the need to plan a capital restructuring that includes a rights issue. This process requires multiple statutory and regulatory approvals, preventing the timely convening of the meeting.

Regulatory Timeline

The original deadline for holding the AGM was September 30, 2026, as per standard requirements for the financial year ended March 31, 2026. The ROC approved the extension vide SRN AC5569272 on September 4, 2026.

Corporate Governance

The Board of Directors will finalize the exact date of the AGM within the extended timeline and communicate it to the stock exchanges in due course. Swaminathan Govindarajan, Whole-time Director, signed the intimation filed with BSE Limited under Regulation 30 of SEBI (LODR) Regulations, 2015.

The ROC advised the company to ensure careful compliance with the Companies Act provisions in future filings.

Indrayani Biotech reported a consolidated net profit of ₹216.03 lakh for the financial year ended March 31, 2026 (FY26), marking a turnaround from the net loss of ₹610.75 lakh recorded in FY25. The company’s board of directors approved the audited standalone and consolidated financial results on August 17, 2026. The results were subsequently published in newspapers on August 20, 2026, in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations.

Consolidated revenue from operations grew 5.8% year-on-year to ₹13,783.12 lakh, up from ₹13,022.84 lakh in the prior year. This growth was largely propelled by the fourth quarter, where revenue surged 44% year-on-year to ₹7,277.90 lakh. In contrast, the standalone segment faced headwinds, with revenue declining 42% to ₹2,189.78 lakh for the full year.

Financial Performance

The consolidated profit before tax stood at ₹29.99 lakh in FY26, compared to a loss of ₹574.35 lakh in FY25. The improvement was supported by a reduction in finance costs, which fell to ₹960.08 lakh from ₹1,176.27 lakh, and lower employee benefit expenses at ₹1,416.15 lakh versus ₹2,046.78 lakh. However, cost of materials consumed increased to ₹9,407.32 lakh from ₹8,277.21 lakh.

On a standalone basis, Indrayani Biotech reported a net profit of ₹69.97 lakh, down from ₹144.63 lakh in FY25. Standalone revenue from operations dropped significantly to ₹2,189.78 lakh from ₹3,776.91 lakh. Other income remained robust at ₹421.25 lakh, contributing substantially to the total income of ₹2,611.03 lakh.

Auditor’s Qualified Opinion

Venkatesh & Co., the statutory auditors, issued a qualified opinion on both the consolidated and standalone financial results. The qualification arises from the inability to ascertain the impact of unconfirmed balances regarding loans, other current assets, and trade receivables. Additionally, the audit noted that two subsidiaries, Matrix Boilers Private Limited and Kniss Laboratories Private Limited, were compiled under Indian GAAP rather than Ind AS, making the impact on the consolidated profit and loss account unascertainable.

Further, the auditor highlighted that HSL Prime Properties Private Limited did not provide balance confirmations for trade creditors aggregating to ₹61.83 lakh, representing approximately 41% of the subsidiary’s total liabilities. Consequently, sufficient appropriate audit evidence could not be obtained for these balances.

What the Numbers Show

A notable divergence exists between the consolidated and standalone results. While the consolidated group turned profitable due to strong operational revenue growth in the subsidiaries, the standalone holding company experienced a sharp contraction in operating revenue. The standalone net profit of ₹69.97 lakh is heavily reliant on other income of ₹421.25 lakh, which constitutes roughly 62% of the total standalone income. This suggests that the core operational profitability of the parent entity has weakened significantly, while the group’s overall health is sustained by its subsidiaries.

Balance Sheet Highlights

As of March 31, 2026, total consolidated assets decreased to ₹25,342.68 lakh from ₹26,816.55 lakh in the previous year. Non-current assets rose slightly to ₹9,470.60 lakh, driven by an increase in capital work in progress to ₹2,669.44 lakh. Cash and cash equivalents improved significantly to ₹425.64 lakh from ₹28.82 lakh, indicating better liquidity management during the year.